---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-006150"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2025-05-02T23:59:59+00:00"
generated_at: "2026-05-22T22:06:15.542902+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Bio-Path announces third pre-clinical milestone for BP1001-A in obesity/Type 2 diabetes

## Summary
- BP1001-A rescues AKT activity decrease in liver cells, preventing insulin resistance.
- Data confirm potential of BP1001-A to treat obesity in Type 2 diabetes patients.
- Pre-clinical testing in HepG2 liver cell model supports earlier results in muscle cells.
- Next step: mouse model study; IND filing expected in 2025 for Phase 1 trial.

## SEC filing metadata
- accession: 0001558370-25-006150
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2025-05-02T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837025006150/0001558370-25-006150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837025006150/bpth-20250501x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-006150
- JSON: https://secwatch.observer/filing/0001558370-25-006150.json
- Plain text: https://secwatch.observer/filing/0001558370-25-006150.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.